IL155704A0 - Combination of gaba agonists and sorbitol dehydrogenase inhibitors - Google Patents

Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Info

Publication number
IL155704A0
IL155704A0 IL15570401A IL15570401A IL155704A0 IL 155704 A0 IL155704 A0 IL 155704A0 IL 15570401 A IL15570401 A IL 15570401A IL 15570401 A IL15570401 A IL 15570401A IL 155704 A0 IL155704 A0 IL 155704A0
Authority
IL
Israel
Prior art keywords
combination
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
gaba
Prior art date
Application number
IL15570401A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL155704A0 publication Critical patent/IL155704A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15570401A 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors IL155704A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (fr) 2000-11-30 2001-11-19 Combinaison d'agonistes gaba et d'inhibiteurs de la sorbitol-deshydrogenase (sdi)

Publications (1)

Publication Number Publication Date
IL155704A0 true IL155704A0 (en) 2003-11-23

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15570401A IL155704A0 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Country Status (38)

Country Link
US (1) US6544998B2 (fr)
EP (1) EP1337271B1 (fr)
JP (1) JP2004514699A (fr)
KR (1) KR20030059290A (fr)
CN (1) CN1477975A (fr)
AP (1) AP2001002360A0 (fr)
AR (1) AR031431A1 (fr)
AT (1) ATE281181T1 (fr)
AU (1) AU2002215159A1 (fr)
BG (1) BG107774A (fr)
BR (1) BR0115783A (fr)
CA (1) CA2430298A1 (fr)
CR (1) CR6964A (fr)
CZ (1) CZ20031399A3 (fr)
DE (1) DE60106968T2 (fr)
DO (1) DOP2001000289A (fr)
EA (1) EA200300432A1 (fr)
EC (1) ECSP034624A (fr)
EE (1) EE200300248A (fr)
ES (1) ES2230378T3 (fr)
HR (1) HRP20030420A2 (fr)
HU (1) HUP0302160A3 (fr)
IL (1) IL155704A0 (fr)
IS (1) IS6786A (fr)
MA (1) MA26964A1 (fr)
MX (1) MXPA03004870A (fr)
NO (1) NO20032441L (fr)
OA (1) OA12534A (fr)
PA (1) PA8534101A1 (fr)
PE (1) PE20020597A1 (fr)
PL (1) PL365927A1 (fr)
PT (1) PT1337271E (fr)
SK (1) SK6192003A3 (fr)
SV (1) SV2003000751A (fr)
TN (1) TNSN01169A1 (fr)
UY (1) UY27042A1 (fr)
WO (1) WO2002043762A2 (fr)
ZA (1) ZA200303381B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
DE60213592T2 (de) 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
JP2007531727A (ja) * 2004-04-02 2007-11-08 インパックス ラボラトリーズ インコーポレーティッド Ｇａｂａｂ受容体アゴニストを含有する即時放出特性および／または制御放出特性を有する薬学的剤形
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
CA2685266C (fr) * 2007-04-27 2014-01-28 Purdue Pharma L.P. Antagonistes de trpv1 et leurs utilisations dans le traitement ou la prevention de la douleur, de l'iu, ainsi que des ulceres, des maladies inflammatoires chroniques de l'intestin ou du colon irritable chez un animal
ES2416723T3 (es) * 2007-10-09 2013-08-02 Merck Patent Gmbh Composiciones farmacéuticas que contienen benfotiamina y gabapentina
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2022531466A (ja) * 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
DK153787C (da) 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
PL350884A1 (en) * 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
PT1041068E (pt) * 1999-04-01 2004-07-30 Pfizer Prod Inc Compostos para o tratamento e prevencao de complicacoes diabeticas

Also Published As

Publication number Publication date
AR031431A1 (es) 2003-09-24
ECSP034624A (es) 2003-07-25
PE20020597A1 (es) 2002-07-08
JP2004514699A (ja) 2004-05-20
PA8534101A1 (es) 2002-10-31
CA2430298A1 (fr) 2002-06-06
NO20032441D0 (no) 2003-05-28
HRP20030420A2 (en) 2004-08-31
PT1337271E (pt) 2005-01-31
WO2002043762A3 (fr) 2003-03-13
AP2001002360A0 (en) 2001-12-31
DE60106968T2 (de) 2005-11-03
AU2002215159A1 (en) 2002-06-11
IS6786A (is) 2003-04-14
WO2002043762A2 (fr) 2002-06-06
KR20030059290A (ko) 2003-07-07
OA12534A (en) 2006-06-05
US20020091128A1 (en) 2002-07-11
HUP0302160A3 (en) 2005-05-30
EA200300432A1 (ru) 2003-10-30
PL365927A1 (en) 2005-01-10
EE200300248A (et) 2003-10-15
ES2230378T3 (es) 2005-05-01
EP1337271B1 (fr) 2004-11-03
DE60106968D1 (de) 2004-12-09
ZA200303381B (en) 2004-04-30
US6544998B2 (en) 2003-04-08
CN1477975A (zh) 2004-02-25
HUP0302160A2 (hu) 2003-11-28
ATE281181T1 (de) 2004-11-15
DOP2001000289A (es) 2003-02-15
BR0115783A (pt) 2003-09-16
TNSN01169A1 (fr) 2005-11-10
UY27042A1 (es) 2002-07-31
NO20032441L (no) 2003-07-03
MXPA03004870A (es) 2003-08-19
MA26964A1 (fr) 2004-12-20
SK6192003A3 (en) 2004-07-07
EP1337271A2 (fr) 2003-08-27
SV2003000751A (es) 2003-01-13
CZ20031399A3 (cs) 2004-04-14
BG107774A (en) 2004-01-30
CR6964A (es) 2004-02-02

Similar Documents

Publication Publication Date Title
IL155704A0 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL155710A0 (en) Combination of gaba agonists and aldose reductase inhibitors
GB0025782D0 (en) Use of inhibitors
EP1383743A4 (fr) Doubles inhibiteurs de la pde 7 et de la pde 4
AU8969601A (en) New use of lipase inhibitors
AU8212901A (en) Deacetylase inhibitors
AU6093201A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL152078A0 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
SI1251848T1 (en) Gyrase inhibitors and uses thereof
PT2270005E (pt) Pró-fármaco de um inibidor de ice
HUP0300061A3 (en) Use of il-18 inhibitors
GB0018164D0 (en) Corrosion inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
HUP0204376A3 (en) Novel invertase inhibitors and methods of use
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
GB0004299D0 (en) Corrosion inhibitors
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
AU1212002A (en) Use of lipase inhibitors
AU4587901A (en) Bisubstrate inhibitors of kinases
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
ZA200205471B (en) Use of IL-18 inhibitors.
AU2001249794A1 (en) Hemoglobinase inhibitors and methods of use
SI1268480T1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer